Jul 15, 2026, 9 items
Oncology - ESR1 Mutated Advanced Breast Cancer Treatment
Vepdegestrant has received approval as a monotherapy for ESR1 mutated, advanced breast cancer.
Also covers Healthcare Management - Physician Workload and Administrative Burden, AI in Medicine - AI-Driven Immune Insights for Sports Medicine, Pharmaceutical Regulation - Camizestrant Regulatory Setback and 5 more.